Skip to main content
Top
Published in: Investigational New Drugs 4/2018

01-08-2018 | PHASE I STUDIES

Radiomics to predict immunotherapy-induced pneumonitis: proof of concept

Authors: Rivka R. Colen, Takeo Fujii, Mehmet Asim Bilen, Aikaterini Kotrotsou, Srishti Abrol, Kenneth R. Hess, Joud Hajjar, Maria E. Suarez-Almazor, Anas Alshawa, David S. Hong, Dunia Giniebra-Camejo, Bettzy Stephen, Vivek Subbiah, Ajay Sheshadri, Tito Mendoza, Siqing Fu, Padmanee Sharma, Funda Meric-Bernstam, Aung Naing

Published in: Investigational New Drugs | Issue 4/2018

Login to get access

Summary

We present the first reported work that explores the potential of radiomics to predict patients who are at risk for developing immunotherapy-induced pneumonitis. Despite promising results with immunotherapies, immune-related adverse events (irAEs) are challenging. Although less common, pneumonitis is a potentially fatal irAE. Thus, early detection is critical for improving treatment outcomes; an urgent need to identify biomarkers that predict patients at risk for pneumonitis exists. Radiomics, an emerging field, is the automated extraction of high fidelity, high-dimensional imaging features from standard medical images and allows for comprehensive visualization and characterization of the tissue of interest and corresponding microenvironment. In this pilot study, we sought to determine whether radiomics has the potential to predict development of pneumonitis. We performed radiomic analyses using baseline chest computed tomography images of patients who did (N = 2) and did not (N = 30) develop immunotherapy-induced pneumonitis. We extracted 1860 radiomic features in each patient. Maximum relevance and minimum redundancy feature selection method, anomaly detection algorithm, and leave-one-out cross-validation identified radiomic features that were significantly different and predicted subsequent immunotherapy-induced pneumonitis (accuracy, 100% [p = 0.0033]). This study suggests that radiomic features can classify and predict those patients at baseline who will subsequently develop immunotherapy-induced pneumonitis, further enabling risk-stratification that will ultimately lead to better treatment outcomes.
Literature
1.
go back to reference Dizon DS, Krilov L, Cohen E, Gangadhar T, Ganz PA, Hensing TA, Hunger S, Krishnamurthi SS, Lassman AB, Markham MJ, Mayer E, Neuss M, Pal SK, Richardson LC, Schilsky R, Schwartz GK, Spriggs DR, Villalona-Calero MA, Villani G, Masters G (2016) Clinical cancer advances 2016: annual report on progress against cancer from the American Society of Clinical Oncology. J Clin Oncol 34(9):987–1011. https://doi.org/10.1200/JCO.2015.65.8427 CrossRefPubMedPubMedCentral Dizon DS, Krilov L, Cohen E, Gangadhar T, Ganz PA, Hensing TA, Hunger S, Krishnamurthi SS, Lassman AB, Markham MJ, Mayer E, Neuss M, Pal SK, Richardson LC, Schilsky R, Schwartz GK, Spriggs DR, Villalona-Calero MA, Villani G, Masters G (2016) Clinical cancer advances 2016: annual report on progress against cancer from the American Society of Clinical Oncology. J Clin Oncol 34(9):987–1011. https://​doi.​org/​10.​1200/​JCO.​2015.​65.​8427 CrossRefPubMedPubMedCentral
4.
go back to reference Naidoo J, Wang X, Woo KM, Iyriboz T, Halpenny D, Cunningham J, Chaft JE, Segal NH, Callahan MK, Lesokhin AM, Rosenberg J, Voss M, Rudin CM, Rizvi H, Hou X, Rodriguez K, Albano M, Gordon RA, Leduc C, Rekhtman N, Harris B, Menzies AM, Guminski AD, Carlino MS, Kong BY, Wolchok JD, Postow MA, Long GV, Hellmann MD (2016) Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy. J Clin Oncol. https://doi.org/10.1200/JCO.2016.68.2005 Naidoo J, Wang X, Woo KM, Iyriboz T, Halpenny D, Cunningham J, Chaft JE, Segal NH, Callahan MK, Lesokhin AM, Rosenberg J, Voss M, Rudin CM, Rizvi H, Hou X, Rodriguez K, Albano M, Gordon RA, Leduc C, Rekhtman N, Harris B, Menzies AM, Guminski AD, Carlino MS, Kong BY, Wolchok JD, Postow MA, Long GV, Hellmann MD (2016) Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy. J Clin Oncol. https://​doi.​org/​10.​1200/​JCO.​2016.​68.​2005
5.
go back to reference Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, Brahmer JR, Lawrence DP, Atkins MB, Powderly JD, Leming PD, Lipson EJ, Puzanov I, Smith DC, Taube JM, Wigginton JM, Kollia GD, Gupta A, Pardoll DM, Sosman JA, Hodi FS (2014) Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 32(10):1020–1030. https://doi.org/10.1200/JCO.2013.53.0105 CrossRefPubMedPubMedCentral Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, Brahmer JR, Lawrence DP, Atkins MB, Powderly JD, Leming PD, Lipson EJ, Puzanov I, Smith DC, Taube JM, Wigginton JM, Kollia GD, Gupta A, Pardoll DM, Sosman JA, Hodi FS (2014) Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 32(10):1020–1030. https://​doi.​org/​10.​1200/​JCO.​2013.​53.​0105 CrossRefPubMedPubMedCentral
6.
go back to reference Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366(26):2443–2454. https://doi.org/10.1056/NEJMoa1200690 CrossRefPubMedPubMedCentral Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366(26):2443–2454. https://​doi.​org/​10.​1056/​NEJMoa1200690 CrossRefPubMedPubMedCentral
9.
go back to reference Gettinger SN, Horn L, Gandhi L, Spigel DR, Antonia SJ, Rizvi NA, Powderly JD, Heist RS, Carvajal RD, Jackman DM, Sequist LV, Smith DC, Leming P, Carbone DP, Pinder-Schenck MC, Topalian SL, Hodi FS, Sosman JA, Sznol M, McDermott DF, Pardoll DM, Sankar V, Ahlers CM, Salvati M, Wigginton JM, Hellmann MD, Kollia GD, Gupta AK, Brahmer JR (2015) Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 33(18):2004–U2032. https://doi.org/10.1200/Jco.2014.58.3708 CrossRefPubMedPubMedCentral Gettinger SN, Horn L, Gandhi L, Spigel DR, Antonia SJ, Rizvi NA, Powderly JD, Heist RS, Carvajal RD, Jackman DM, Sequist LV, Smith DC, Leming P, Carbone DP, Pinder-Schenck MC, Topalian SL, Hodi FS, Sosman JA, Sznol M, McDermott DF, Pardoll DM, Sankar V, Ahlers CM, Salvati M, Wigginton JM, Hellmann MD, Kollia GD, Gupta AK, Brahmer JR (2015) Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 33(18):2004–U2032. https://​doi.​org/​10.​1200/​Jco.​2014.​58.​3708 CrossRefPubMedPubMedCentral
10.
go back to reference Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, Carcereny E, Ahn MJ, Felip E, Lee JS, Hellmann MD, Hamid O, Goldman JW, Soria JC, Dolled-Filhart M, Rutledge RZ, Zhang J, Lunceford JK, Rangwala R, Lubiniecki GM, Roach C, Emancipator K, Gandhi L, Investigators K-001 (2015) Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372(21):2018–2028. https://doi.org/10.1056/NEJMoa1501824 CrossRefPubMed Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, Carcereny E, Ahn MJ, Felip E, Lee JS, Hellmann MD, Hamid O, Goldman JW, Soria JC, Dolled-Filhart M, Rutledge RZ, Zhang J, Lunceford JK, Rangwala R, Lubiniecki GM, Roach C, Emancipator K, Gandhi L, Investigators K-001 (2015) Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372(21):2018–2028. https://​doi.​org/​10.​1056/​NEJMoa1501824 CrossRefPubMed
11.
go back to reference Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, Linette GP, Meyer N, Giguere JK, Agarwala SS, Shaheen M, Ernstoff MS, Minor D, Salama AK, Taylor M, Ott PA, Rollin LM, Horak C, Gagnier P, Wolchok JD, Hodi FS (2015) Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 372(21):2006–2017. https://doi.org/10.1056/NEJMoa1414428 CrossRefPubMedPubMedCentral Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, Linette GP, Meyer N, Giguere JK, Agarwala SS, Shaheen M, Ernstoff MS, Minor D, Salama AK, Taylor M, Ott PA, Rollin LM, Horak C, Gagnier P, Wolchok JD, Hodi FS (2015) Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 372(21):2006–2017. https://​doi.​org/​10.​1056/​NEJMoa1414428 CrossRefPubMedPubMedCentral
16.
go back to reference Colen RR, Piwnica-Worms D (2016) Radiomics and radiogenomics in breast cancer. Breast Dis 27(1):23–24 Colen RR, Piwnica-Worms D (2016) Radiomics and radiogenomics in breast cancer. Breast Dis 27(1):23–24
17.
go back to reference Aerts HJWL, Velazquez ER, Leijenaar RTH, Parmar C, Grossmann P, Carvalho S, Bussink J, Monshouwer R, Haibe-Kains B, Rietveld D, Hoebers F, Rietbergen MM, Leemans CR, Dekker A, Quackenbush J, Gillies RJ, Lambin P (2014) Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach (vol 5, pg 4006, 2014). Nat Commun 5. https://doi.org/10.1038/ncomms5644 Aerts HJWL, Velazquez ER, Leijenaar RTH, Parmar C, Grossmann P, Carvalho S, Bussink J, Monshouwer R, Haibe-Kains B, Rietveld D, Hoebers F, Rietbergen MM, Leemans CR, Dekker A, Quackenbush J, Gillies RJ, Lambin P (2014) Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach (vol 5, pg 4006, 2014). Nat Commun 5. https://​doi.​org/​10.​1038/​ncomms5644
18.
go back to reference Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN, et al. (2003) CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13(3):176-81. doi:10.1016/S1053-4296(03)00031-6 Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN, et al. (2003) CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13(3):176-81. doi:10.​1016/​S1053-4296(03)00031-6
20.
go back to reference Clausi DA (2002) An analysis of co-occurrence texture statistics as a function of grey level quantization. Can J Remote Sens 28(1):45–62CrossRef Clausi DA (2002) An analysis of co-occurrence texture statistics as a function of grey level quantization. Can J Remote Sens 28(1):45–62CrossRef
23.
go back to reference Papoulis A (1991) Probability, random variables, and stochastic processes. New York: McGraw-Hill Papoulis A (1991) Probability, random variables, and stochastic processes. New York: McGraw-Hill
27.
go back to reference Anguita D, Ghio A, Greco N, Oneto L, Ridella S (2010) Model selection for support vector machines: Advantages and disadvantages of the machine learning theory", International Joint Conference on Neural Networks. doi:10.1109/IJCNN.2010.5596450 Anguita D, Ghio A, Greco N, Oneto L, Ridella S (2010) Model selection for support vector machines: Advantages and disadvantages of the machine learning theory", International Joint Conference on Neural Networks. doi:10.​1109/​IJCNN.​2010.​5596450
28.
go back to reference Syed Z, Saeed M, Rubinfeld I (2010) Identifying high-risk patients without labeled training data: anomaly detection methodologies to predict adverse outcomes. AMIA Ann Symp Proc 2010:772–776 Syed Z, Saeed M, Rubinfeld I (2010) Identifying high-risk patients without labeled training data: anomaly detection methodologies to predict adverse outcomes. AMIA Ann Symp Proc 2010:772–776
29.
go back to reference Christiansen P, Nielsen LN, Steen KA, Jorgensen RN, Karstoft H (2016) DeepAnomaly: combining background subtraction and deep learning for detecting obstacles and anomalies in an agricultural field. Sensors (Basel) 16(11). doi:https://doi.org/10.3390/s16111904 Christiansen P, Nielsen LN, Steen KA, Jorgensen RN, Karstoft H (2016) DeepAnomaly: combining background subtraction and deep learning for detecting obstacles and anomalies in an agricultural field. Sensors (Basel) 16(11). doi:https://​doi.​org/​10.​3390/​s16111904
Metadata
Title
Radiomics to predict immunotherapy-induced pneumonitis: proof of concept
Authors
Rivka R. Colen
Takeo Fujii
Mehmet Asim Bilen
Aikaterini Kotrotsou
Srishti Abrol
Kenneth R. Hess
Joud Hajjar
Maria E. Suarez-Almazor
Anas Alshawa
David S. Hong
Dunia Giniebra-Camejo
Bettzy Stephen
Vivek Subbiah
Ajay Sheshadri
Tito Mendoza
Siqing Fu
Padmanee Sharma
Funda Meric-Bernstam
Aung Naing
Publication date
01-08-2018
Publisher
Springer US
Published in
Investigational New Drugs / Issue 4/2018
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-017-0524-2

Other articles of this Issue 4/2018

Investigational New Drugs 4/2018 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine